Ovarian cancer has the highest mortality rate of the """"""""women's cancers"""""""" (breast and gynecologic cancers). The Mayo Clinic SPORE in Ovarian Cancer features a team of basic, clinical, and population science Investigators conducting translational research designed to reduce the burden of ovarian cancer. The translational science of this SPORE includes four projects. Project 1, """"""""Poisoning of PARP and topoisomerase I to treat ovarian cancer,"""""""" studies the effect of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-888 alone and In combination with topotecan. In addition to elucidating how ABT-888 converts PARP Into an enzyme that actively contributes to the demise of topotecan-treated ovarian cancer cells, this project will examine a series of tumor markers for their ability to predict response in a topotecan/ABT-888 phase II trial. Project 2, """"""""Mechanisms of immunosuppression in ovarian cancer,"""""""" our population sciences project, studies the components of microenvironmental immunosuppression in ovarian cancer. Based in a large cohort of ovarian cancer cases, the work will examine differences in inherited variation in regulatory T-cell-related genes, the quantity of Tregs In the microenvironment and outcome after diagnosis. Project 3. """"""""Optimizing measles virotherapy in the treatment of recurrent ovarian cancer,"""""""" builds upon our in vitro and phase I clinical trial data showing promising anti-tumor activity with the attenuated vaccine strain of measles virus delivered intraperitoneally in women with recurrent ovarian cancer. In this project we will study the possibility of systemic administration of the virus and measures to enhance cytotoxicity of the virus. Project 4. """"""""Flavopiridol reverses platinum resistance in ovarian cancer,"""""""" builds upon work at Mayo showing that flavopiridol combines with cisplatin to yield cytotoxic synergy. We completed a phase I trial of this combination and now in a phase II trial in platinum-resistant ovarian cancer, have observed a 33% response rate, which is twice the mean response rate typically seen in this setting. This project will study the mechanism of synergy and attempt to improve upon the combination by adding a third agent and/or identifying predictive biomarkers in tumor samples from responders vs. non-responders. Four cores (Administration, Biospecimens/Patient Registry, Animal Models, and Biostatistics) provide the infrastructure support for the translational research of the SPORE. A Developmental Research Program has been established to foster promising research initiatives;and a Career Development Program will promote the research careers of junior or more established investigators who wish to pursue ovarian cancer translational research. The Mayo Clinic SPORE in Ovarian Cancer has the full support of the Mayo Clinic Cancer Center and Mayo Foundation.

Public Health Relevance

Of the women's cancers (breast and gynecologic cancers), ovarian cancer has the highest mortality rate. In this SPORE application, we explore one important pathogenic process -- immunosuppression -- that underlies ovarian cancer and three novel, promising treatment approaches for this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA136393-05S1
Application #
8927889
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Arnold, Julia T
Project Start
2009-09-01
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
$622,294
Indirect Cost
$228,712
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Amos, Christopher I; Dennis, Joe; Wang, Zhaoming et al. (2017) The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 26:126-135
Babic, Ana; Cramer, Daniel W; Kelemen, Linda E et al. (2017) Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control 28:459-468
Li, Yunhui; Luo, Kuntian; Yin, Yujiao et al. (2017) USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response. Nat Commun 8:15752
Butler, Kristina A; Hou, Xiaonan; Becker, Marc A et al. (2017) Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. Neoplasia 19:628-636
Wang, Chen; Armasu, Sebastian M; Kalli, Kimberly R et al. (2017) Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. Clin Cancer Res 23:4077-4085
Ovarian Tumor Tissue Analysis (OTTA) Consortium (2017) Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol 3:e173290
Kar, Siddhartha P; Adler, Emily; Tyrer, Jonathan et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer 116:524-535
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Dicks, Ed; Song, Honglin; Ramus, Susan J et al. (2017) Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget 8:50930-50940
Nounamo, Bernice; Liem, Jason; Cannon, Martin et al. (2017) Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model. Mol Ther Oncolytics 6:90-99

Showing the most recent 10 out of 269 publications